Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma(LUMEN-1) | recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jun 15, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 |
| clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT02846987 | Study of Abemaciclib in Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04871282 | A Study of AL102 in Patients With Progressing Desmoid Tumors(RINGSIDE) | active not recruiting | Phase 2 / Phase 3 | 198 | Immunome, Inc.INDUSTRY | 11 | Jun 8, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST(PEMIGIST) | recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602049 | Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03643133 | Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients(SARCOME13) | active not recruiting | Phase 2 | 60 | UNICANCEROTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT03598595 | Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma | active not recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05425004 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | recruiting | Phase 2 | 24 | Baptist Health South FloridaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06275919 | Regorafenib for Recurrent Meningioma (MIRAGE Trial)(MIRAGE) | recruiting | Phase 2 | 104 | Istituto Oncologico Veneto IRCCSOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04807816 | Targeting ATR in Soft-tissue Sarcomas(TARSARC) | completed | Phase 2 | 58 | Institut BergoniéOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07357519 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | recruiting | Phase 1 / Phase 2 | 55 | Lantheus Medical ImagingINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07541430 | A Study in Adults With Desmoid Tumors | recruiting | Phase 2 | 50 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07550582 | Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction(SAVE-GEJ) | enrolling by invitation | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06820164 | Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride | recruiting | Phase 1 / Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04082520 | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | recruiting | Phase 2 | 42 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05019703 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04659811 | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | active not recruiting | Phase 2 | 35 | Nancy Ann Oberheim Bush, MDOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05661643 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST(GIST) | recruiting | Phase 2 | 29 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05905887 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06326346 | GIST Oral Paclitaxel(Liporaxel) | recruiting | Phase 2 | 28 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma(CabOSTar) | terminated | Phase 2 | 10 | IpsenINDUSTRY | 10 | Mar 31, 2026 | clinicaltrials |
| NCT04305548 | Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma(ISG-MCS) | recruiting | Phase 2 | 16 | Italian Sarcoma GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05152173 | Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis | completed | Phase 2 | 176 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | recruiting | Phase 1 / Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2026source: clinicaltrials